CHICAGO, Sept. 16, 2011 /PRNewswire/ -- Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide.
CEM-101 is a fluoroketolide belonging to the macrolide class and is the first macrolide since azithromycin with the potential for both intravenous (IV) and oral administration. The compound has potent in vitro activity against respiratory pathogens such as pneumococci, including macrolide- and quinolone-resistant strains. Bacterial pneumonia caused by multi-drug resistant pneumococci has a significant impact on morbidity and mortality due to high treatment failure rates and subsequently increases hospitalization and healthcare costs. CEM-101 has completed Phase 2 trials in community-acquired bacterial pneumonia (CABP) for the oral dosage form and is in Phase 1 for the IV dosage form.
"Data presented at this year's ICAAC conference contributes additional data on the safety, tolerability and dosing profile of our fourth generation macrolide, CEM-101," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra. "Our efforts are centered around developing an injectable macrolide that -- causes less pain on injection than traditional macrolides and that provides physicians with the possibility of initiating patients on an antibiotic in the hospital then stepping down therapy to oral administration to send the patient home on the same antibiotic. In addition, we have extended the structure-side effect relationships of our studies on telithromycin's (Ketek®) nicotinic acetylcholine receptor activity to examine drugs outside the macrolide class. This study links visual changes to inhibition of nicotinic acetylcholine receptor binding by certain triazole antifungals. It provides further support for the results previously reported for the possible cause of the visual accommodation effects seen with telithromycin while CEM-101, as well as older macrolides, have not demonstrated significant receptor antagonistic activity."
CEM-101 can be administered intravenously without pain in a rabbit ear vein model
Macrolides are a potent class of antibiotics that have been valuable for treating respiratory infections. However, because they have been available usually as orally-administered agents their use has been generally limited to the community setting. Erythromycin and azithromycin has been available in the U.S. as an intravenous form but their use has been limited because of pharmacologically-related pain on injection. Fernandes et al. (Abst. A2-036) investigated the level of pain caused by infusion of CEM-101 as single or multiple doses compared to azithromycin into rabbit ear veins. In the single-dose study, they found that of up to 3 mg/ml of CEM-101 did not elicit a pain response at infusion rates of up to 4 ml/min. In contrast, rabbits injected with IV azithromycin (2 mg/ml), the dose approved for hospital administration, exhibited strong movements that are associated with a pain response.
In the multidose study, CEM-101, infused at concentrations of two and three mg/ml, did not generate a pain signal for up to five days of administration. Injection site reaction was noted on days three through five but a similar response was observed when only the formulation vehicle was injected.
Further evidence that inhibition of specific nicotinic acetylcholine receptors may be responsible for some of the adverse events seen with telithromycin
Side effects caused by the ketolide, telithromycin, including reversible blurred vision, muscle weakness and liver failure were related to inhibition of the alpha7 and the ganglionic alpha3beta4 nicotinic receptor. CEM-101 and other macrolides did not show the high level of inhibition demonstrated by telithromycin and those macrolides do not evoke telithromycin-associated adverse events. Bertrand et al (Abst. A2-588) investigated activity of triazole antifungal agents, members of which do exhibit some side effects similar to telithromycin. The authors demonstrated that voriconazole, which possesses a pyrimidine moiety and has been associated with visual disturbances, inhibits the ganglionic alpha3beta4 nicotinic acetylcholine receptor. Fluconazole, which does not contain a pyrimidine moiety and is not associated with visual disturbances, does not.
CEM-101 is the first fluoroketolide with a number of attributes that may provide clinically important advantages over several comparator products. Our clinical trials and pre-clinical studies have shown that CEM-101, with its unique chemical structure, has:
- a favorable safety and tolerability profile;
- comparable efficacy to the current standard of care;
- potent activity against a broad range of bacteria with excellent tissue distribution and intracellular activity;
- a lower incidence of resistance development;
- IV, oral and suspension formulations that allow it to be used in all patient populations and settings; and
- anti-inflammatory qualities to help patients feel better sooner during treatment.
The annual incidence for CABP in the United States is over five million of which over one million are hospitalized (File, T.M., Lancet, 2003; File, T.M. and Tan, J.S. JAMA, 2005; CDC, National Hospital Discharge Survey, 2006; File, T.M. and Marrie, T., Postgrad. Med., 2010). There is a growing need for new drugs that are well tolerated and that may be administered both orally and intravenously to address the crisis of emergent drug resistance. Cempra has licensed exclusive worldwide rights from Optimer Pharmaceuticals, Inc., except in the Association of Southeast Asian Nations (ASEAN) countries, to discover, develop and commercialize macrolides from a library of more than 500 compounds from Optimer's OPopS drug discovery platform, including CEM-101.
About Cempra Pharmaceuticals
Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs in the treatment of infectious diseases caused by bacteria. Our two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.
Dr. Prabhavathi Fernandes
President and Chief Executive Officer
SOURCE Cempra Pharmaceuticals